Study of sacituzumab govitecan for HER2-negative breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how well a drug called sacituzumab govitecan works and how safe it is for people with a certain type of breast cancer that has spread (HER2-negative metastatic breast cancer). It aims to understand real-world results for patients in China.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer has come back in the area where it started or spread to other parts of the body, and you are healthy enough for chemotherapy.
- Your breast cancer is HER2-negative, meaning it doesn't have a certain protein.
- You are between 18 and 75 years old.
- You are in fairly good health (able to do daily activities with some help if needed).
- You have at least one tumor that can be measured on a scan.
- You have already received at least two cycles (doses) of the study drug, sacituzumab govitecan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the drug Sacituzumab Govitecan works in real-life settings for people with certain types of advanced breast cancer that have not responded to prior treatments.
This trial tests a new drug, Sacituzumab Govitecan, for people with advanced triple-negative breast cancer that hasn't been treated yet. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
This study is tracking how people with metastatic triple-negative breast cancer feel and function during treatment with sacituzumab govitecan or other chemotherapy. It aims to understand real-world benefits from the patient's perspective.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
This trial tests a drug called Sacituzumab Govitecan for people with HR+/HER2- advanced or metastatic breast cancer that has stopped responding to a CDK4/6 inhibitor. It looks at whether the drug can slow down the cancer and requires you to have a tumor biopsy.
Hear when a new Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.